Ginsenoside Rg1 triggers ferroptosis to inhibit hepatocellular carcinoma via SLC7A11 downregulation
Anwei Wei, Zhenzhen Liu, Fei Zhao, Yipu Zhao, Bowei Liu · 2026
Read Ginsenoside Rg1 triggers ferroptosis to inhibit hepatocellular carcinoma via SLC7A11 downregulation by Anwei Wei, Zhenzhen Liu, Fei Zhao, Yipu Zhao, Bowei Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13522317.txt.
Description
Anwei Wei and colleagues show in 2026 that ginsenoside Rg1, a ginseng compound, forces liver cancer cells into ferroptosis, an iron-driven death route that can bypass standard resistance. Liver cancer often presents late, leaving systemic therapy as the main option.
Rg1 slowed growth and migration of liver cancer cells in laboratory tests. Treated cells displayed hallmark ferroptosis features, linking benefit to that death pathway rather than generic toxicity. A cystine transporter called SLC7A11 fell under treatment, restoring ferroptosis sensitivity, although the authors note that its mediator role still needs functional validation. The findings support ferroptosis-targeted combinations for hard-to-treat liver cancer.
Catalog record
| CREATOR | Anwei Wei, Zhenzhen Liu, Fei Zhao, Yipu Zhao, Bowei Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24892 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |